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ones or DPP-4 was associated with reduced risks for cardiovascular events (hazard 
ratio, 0.69; 95% CI, 0.57 to 0.84; P< 0.001 and hazard ratio, 0.71; 95% CI, 0.60 to 0.84; 
P< 0.001, respectively). ConClusions: Among patients with type 2 diabetes who 
were initiating oral diabetes drugs, metformin use was significantly associated with 
a decreased risk of major adverse cardiovascular events. And, the addition of thiazo-
lidinediones or DPP-4 inhibitors vs sulfonyurea on metformin was associated with 
a decreased cardiovascular risk.
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objeCtives: As the effects of statin use on type 2 diabetes mellitus (T2D) are not 
clearly determined, this study evaluated the risk of T2D as well as the benefit of 
cardiovascular disease in the relationship with statin use. Methods: We identi-
fied 5,441071 patients who were eligible for statin therapy and aged 40 years and 
older among National Health Insurance Examinees between January 1, 2005, and 
December 31, 2012. We evaluated the clinical impact of statin use on primary and 
secondary outcome. In addition, we compared the effect of duration or intensity of 
statin use. The primary outcome was new-onset T2D and the secondary outcomes 
included a composite of cardiovascular death, myocardial infarction or stroke, and 
all-cause death. Outcome data were linked with the national claims data of hospital 
admissions and national vital statistics through December 31, 2014. Propensity-
score matching was used to assemble a cohort of patients with similar baseline 
characteristics. Results: A total of 332,449 patients met the inclusion criteria, of 
whom 23,970 (7.21%) used statin therapy. Among them, 23082 pairs was matched 
by propensity-score method, with the consideration of baseline demographic, 
clinical characteristics, comorbidities, and concomitant cardiovascular medication 
factors. ConClusions: The final results of the primary and secondary study out-
comes will be available at ISPOR 18th Annual Euroepan Congress. This large-scale, 
population-based observational study lined with national claim data will provides 
a critical appraisal of effectiveness on new-onset of type 2 diabetes mellitus as well 
as cardiovascular events of statin use.
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objeCtives: Hypertriglyceredemia (HTG) is reported to be associated with acute 
pancreatitis (AP) as an etiological factor and an epiphenomenon. However, evidence 
to establish underlying correlation between TG levels and AP severity is not well 
established. This review was designed to analyse the correlation between acute pan-
creatitis (AP) and increased triglyceride (TG) levels thus defining the etiological role 
of elevated TG levels in AP patients. Methods: A comprehensive search strategy 
was developed and a systematic literature search in Pubmed and EMBASE from 1996 
to June 1, 2015 was carried out to identify studies mentioning triglycerides (TG) and 
acute pancreatitis (AP). Studies were screened using pre-defined inclusion criteria 
after which data from included trials were extracted, by two independent review-
ers and disagreements resolved by a third reviewer. The data was extracted into a 
data extraction form by one reviewer and a thorough quality check was performed 
by the other independent reviewer. Results: Of the 3,797 identified abstracts, 54 
unique studies were included in this review. The majority of the studies reported 
hypertriglyceridemia as an etiology of AP. Only four studies indicated a quantitative 
correlation between elevated TG levels and risk of AP. Amongst these studies, higher 
risk of AP among patients with moderate (150 to 499 mg/dL) and severe HTG (≥ 500 
mg/dL) was reported. Burden of disease (hospital length of stay and mortality) was 
significantly higher in the HTG-induced AP patients than other etiological forms of 
AP. ConClusions: There is paucity of a concrete body of evidence quantifying the 
role of TG levels and risk of AP. Randomized, placebo-controlled trials to determine 
role of TG in AP are highly desirable to substantiate the evidence gaps.
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objeCtives: Healthcare policy for reducing cardiovascular (CV) event burden 
should be guided by current and generalisable data. The objective of the study was 
to estimate 1-year CV event rates in a high-risk general population cohort in the 
UK. Methods: The UK THIN Database was utilised, with inclusion criteria of age 
≥ 18 years and evidence of a high-risk condition for CV events (prior CV disease 
[CVD], diabetes, or chronic kidney disease [CKD]) as of Jan 1, 2010 (index; initiation 
of follow-up). Both treated and untreated patients were included. Patient subgroups 
within CVD were: acute coronary syndrome (ACS) ≤ 12 months pre-index; ACS 12-24 
months pre-index; history of ischaemic stroke; other coronary heart disease (CHD); 
and peripheral arterial disease (PAD). These subgroups were not mutually exclusive 
due to the potential of multiple CVD conditions. Other subgroups included diabetes 
without CVD, and CKD without CVD. One-year risk for the composite endpoint of 
ACS (myocardial infarction or unstable angina), coronary revascularisation, ischae-
mic stroke, and CV death (estimated as 62% of all-cause death based on published 
sources) was estimated via Kaplan-Meier (KM) analyses. Results: A total of 339,943 
individuals met inclusion criteria. Estimated 1-year event rates (%, based on KM 
analysis) for the composite endpoint were: ACS ≤ 12 months, 12.9 (95% CI 11.3-
objeCtives: Heart Fatilure (HF) has become a public health problem reaching epi-
demic levels especially for the elderly population. The objetive of this study was the 
description of patients with HF been treated (followed) in a primary care (PC) area 
in Madrid by the use of data extracted from electronic medical records. Methods: 
A retrospective study was carried out to follow a cohort of 224,320 patients (18yo or 
older visiting PC at least once in 2006) from 01/01/2006 to 12/31/2010. Study outcomes: 
HF prevalent and incident cases, mortality of HF, time diagnosis to dead, GP, Nurse, 
cardiologist visit, hospitalizations and treatment (grouped by ATC-code). Results: 
HF prevalence during the period of study was 2.09% (4,680 patients), 63% women. Of 
these prevalent patients, 1,356 were diagnosed before 2006. The mean age of diagnose 
was 77.28 years (SD 11.52), 74.96 years for males (SD 11.53) and 78.65 (SD 11.29) for 
females. Incident cases during the study period was 3,324 (631 in 2006, 652 in 2007, 
677 in 2008, 703 in 2009 and 661 in 2010). 1,106 had at least one admisión to hospi-
tal. Average number of admisions 1.618 (SD 1.086). And 1028 patients died (22.61%). 
Average time from diagnosis to dead was 1,162 days (SD 1,064). The average yearly 
rate of visits per patient was 14.17 (SD 8.03) for GPs and 10.22 (SD 9.03) for Nurses, 
for consultant cardiologist was 0.10 (SD 0.16). The patients treatment mainly include 
Diuretics (72.93% of patients), Antithrombotic agents (70.96%), Agents acting on the 
renin-angiotensin system (69.89%), Calcium channel blockers (49.12%), Drugs used in 
diabetes (44.89%), Lipid modifying agents (44.17%), Cardiac therapy (38.29%) and Beta 
Blocking agents (37.63%). ConClusions: Despite the improvement of pharmacologi-
cal treatments and the better control of the cardiovascular risk factors. HF continues 
to be responsible for high mortality and a high resource consumption.
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objeCtives: To describe the characteristics and treatment of patients having a 
myocardial infarction (MI) and estimate the incidence of cardiovascular events 
following the index MI, in the French Health Insurance database. Methods: A 
cohort of patients who had an MI in France between 2007 and 2011 was extracted 
from a claims database: the Echantillon Généraliste de Bénéficiaires (a 1% repre-
sentative sample of subjects covered by the general health insurance (≈600,000 
patients). The incidence of cardiovascular events following the index MI was esti-
mated using the Kaplan Meier method. A cox survival model aims to identify fac-
tors related to the composite outcome (death/MI/stroke). Results: 1,920 subjects 
were identified with an index MI: 2/3 were males, mean age= 67.2 y, 20.6% had 
diabetes, 37.6% hypercholesterolemia and 82.4% hypertension. Compared to the 
6 months preceding the index MI, rates of use of medications increased in the 
6 months following MI for statins (91.1%/30.7%), Aspirin+other antiplatelet agent 
(82.1%/7.1%), class III antiarrhythmics (8.4%/2.4%), oral anticoagulants (10.1%/5.1%), 
non thiazide diuretics (32.9%/19.1%), ACE-inhibitors (71%/18.6%), beta-blockers 
(86.0%/26.5%), and nitrates (46.4%/9.9%). Cumulative incidences at 1, 2 and 3 years 
after the index MI were: For deaths (all cause and including in-hospital death): 
17.8% (CI95%= 16.0%;19.5%), 21.6% (CI95%= 20.7%;23.5%), 27.0% (CI95%= 25.8%;29.1%); 
For MI (recurrence): 3.1% (CI95%= 2.3%;3.8%), 4.1% (CI95%= 3.2%;5.0%%), 4.7% 
(CI95%= 3.7%;5.7%); For stroke (or transit ischemic attack): 1.9% (CI95%= 1.3%;2.5%), 
3.1% (CI95%= 2.3%;3.9%%), 4.1% (CI95%= 3.1%;5.0%); For the composite outcome 
(death/MI/stroke) : 20.7% (CI95%= 18.9%;22.5%), 26.0% (CI95%= 24.0%;28.0%), 32.1% 
(CI95%= 29.8%;34.3%). A cox multivariate survival model identified the follow-
ing independent correlates of the composite outcome: age (ref < 60y) (60-70y: 
HR= 2.071 CI= [1.051;2.820], 70-80y: HR= 3.463 CI= [2.640;4.541], > 80y: HR= 7.124 
CI= [5.946;9.235]), diabetes (HR= 1.229,CI= [1.028;1.469]) percutaneous coronary inter-
vention (HR= 0.579,CI= [0.457;0.689]), and coronary artery bypass grafting (HR= 0.5
58,CI= [0.359;0.869] ConClusions: Despite high rates of prescription of medical 
therapy, all-cause mortality and CV event rates remained high following MI. This 
underscores the need to improve secondary prevention.
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objeCtives: The cardiovascular outcomes of oral antidiabetic drugs in type 2 diabe-
tes are still unknown. Methods: We identified 1,035,824 patients with type 2 who 
initiated oral antidiabetic drugs in Korea between January 1, 2005, and December 
31, 2011, using national claim data, and outcome data were linked with the national 
registries of hospital admissions and vital statistics. Our study evaluated the cardio-
vascular effects of metformin as initial pharmacotherapy and different second-line 
agents added on metformin. The primary outcome was a composite of cardiovas-
cular death, myocardial infarction, or ischemic stroke, and the follow-up was per-
formed through December 31, 2013 Results: Among 423,081 patients who are 
initiating oral antidiabetic drugs, 208,990 (49.4%) began diabetes treatment with 
metformin. During 3 years of follow-up, the adjusted risk of primary outcomes 
was significantly lower in the metformin user than in the metformin non-user 
(hazard ratio, 0.94; 95% CI, 0.91 to 0.97; P < 0.001). Among 157,509 patients who were 
requiring second-line agents add-on metformin, 123,830 (78.6%) used sulfonylureas, 
9,848 (6.3%) used thiazolidinediones, and 23,831 (15.1%) used dipeptidyl peptidase 
4 [DPP-4] inhibitors. Compared with sulfonyurea, the addition of thiazolidinedi-
